In the last trading session, 1.55 million Perspective Therapeutics Inc (AMEX:CATX) shares changed hands as the company’s beta touched 1.11. With the company’s per share price at $2.73 changed hands at $0.1 or 3.80% during last session, the market valuation stood at $202.64M. CATX’s last price was a discount, traded about -519.05% off its 52-week high of $16.90. The share price had its 52-week low at $1.60, which suggests the last value was 41.39% up since then.
Analysts gave the Perspective Therapeutics Inc (CATX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CATX as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Instantly CATX was in green as seen at the end of in last trading. With action 8.76%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -14.42%, with the 5-day performance at 8.76% in the green. However, in the 30-day time frame, Perspective Therapeutics Inc (AMEX:CATX) is 40.72% up.
The consensus price target for the stock as assigned by Wall Street analysts is 21, meaning bulls need an upside of 87.0% from its current market value. According to analyst projections, CATX’s forecast low is 3 with 24 as the target high. To hit the forecast high, the stock’s price needs a -779.12% plunge from its current level, while the stock would need to soar -9.89% for it to hit the projected low.
Perspective Therapeutics Inc (CATX) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.86%. The 2025 estimates are for Perspective Therapeutics Inc earnings to increase by 7.47%, but the outlook for the next 5-year period is at -1.62% per year.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund. With 1.69 shares estimated at $4.63 million under it, the former controlled 2.28% of total outstanding shares. On the other hand, Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund held about 2.21% of the shares, roughly 1.64 shares worth around $4.49 million.
